Lymphoproliferative infiltrates could be seen in several skin diseases but they are very characteristic of cutaneous pseudolymphoma, which can mimic both clinically and histopathologically cutaneous malignant pseudolymphoma.
Lymphoproliferative infiltrations are observed in a number of dermatoses but are particularly typical of the cutaneous pseudolymphomas which can stimulate malignant lymphomas both clinically and histologically (1) .
The differential diagnosis between cutaneous pseudolymphomas and malignant cutaneous lymphomas may present a serious problem together with the possibility for the transformation of the cutaneous pseudolymphomas into cutaneous lymphomas (1, 3) .
A number of authors seek a possible connection between the occurrence of cutaneous pseudolymphoma and preceding drug intake. A broad spectrum of medications are capable of inducing the occurrence of cutaneous pseudolymphomas (2, 3, 4) .
The drug-induced pseudolymphomas can be divided into:
1. Induced by anticonvulsants 2. Induced by other drugs. Cutaneous pseudolymphoma induced by anticonvulsants (Pheniytion, etc.) develops during the first 2 to 8 months following the administration of the drug but can occur much earlier (5 days) or much later (up to 5 years) after the onset of the treatment (2).
Clinically, it presents with febrility, lymphadenopathy, hepatosplenomegaly, blood eosinophilia and eryhtemic eruption under the form of single papules, plaques and nodules, but occasionally, the lesions may be generalized. Erythrodermia has also been described, stimulating the Sezàry's syndrome with the typical cells in the peripheral blood (Adams, Braddock et al.,Harris et àl., Wolf et àl.). In Bulgaria, a case has been reported about a patient with erythrodermia, febrility, lymphadenopathy and blood eosinophilia, with a histological picture of Micosis Fungoides from the skin biopsy caused by treatment with Carbamazepine(Kavaklieva, Balabanova, Cankov).
The cutaneous pseudolymphomas may also be induced by other drugs (4, 5):
-Neuroleptics -ACE-inhibitors -β-blockers -Antihistamines -Cytostatics
These drug-induced cutaneous pseudolymphomas occur one month to one year following the administration of the therapy. Localized papules are observed together with single or multiple nodules and plaques, generalized papulonodular lesions and exfoliating erythrodermia resembling the Sezàry's syndrome (Ploysamgam et àl.).
It is considered that in lymphatoid drug eruption, the immunological function is reduced and the immune control is impaired, leading to abnormal proliferation of lymphocytes, increased function of the T-suppressors and hypogamaglobulinemia. Relative increase in the absolute number of the peripheral T-lymphocytes by 85-95 % (5, 6).
DISCUSSION:
1. The differentiation of cutaneous pseudolymphoma from malignant cutaneous lymphoma presents a differential diagnostic problem for the clinical practice.
2. Drug-induced pseudolymphomas are due to reduced immune control leading to abnormal proliferation of lymphocytes and enhanced functioning of the T-suppressors.
3. The impaired immune control and the accompanying immunological processes can complicate the clinical manifestations toward the development of Micosis Fungoides.
4. When applying drug groups in chronic conditions, the possibility should be envisaged for the development of drug-induced pseudolymphoma.
5. In cases of developed pseudolymphoma as a result of drug administration, the latter must be discontinued or replaced for a more appropriate group with another chemical composition.
